These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20580203)

  • 1. Antipsychotic drug side effects for persons with intellectual disability.
    Matson JL; Mahan S
    Res Dev Disabil; 2010; 31(6):1570-6. PubMed ID: 20580203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The convergent and divergent validity of the Matson Evaluation of Drug Side-effects (MEDS) and the Dyskinesia Identification System: Condensed User Scale (DISCUS).
    Matson JL; Fodstad JC; Rivet TT
    J Intellect Dev Disabil; 2008 Dec; 33(4):337-44. PubMed ID: 19039694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tardive dyskinesia and intellectual disability: an examination of demographics and topography in adults with dual diagnosis and atypical antipsychotic use.
    Fodstad JC; Bamburg JW; Matson JL; Mahan S; Hess JA; Neal D; Holloway J
    Res Dev Disabil; 2010; 31(3):750-9. PubMed ID: 20207106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of the Matson Evaluation of Drug Side Effects (MEDS).
    Matson JL; Cervantes PE
    Res Dev Disabil; 2013 May; 34(5):1849-53. PubMed ID: 23528442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: treatment or mistreatment?
    Tsiouris JA
    J Intellect Disabil Res; 2010 Jan; 54(1):1-16. PubMed ID: 20122096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Examination of Psychotropic Medication Side Effects: does taking a greater number of psychotropic medications from different classes affect presentation of side effects in adults with ID?
    Mahan S; Holloway J; Bamburg JW; Hess JA; Fodstad JC; Matson JL
    Res Dev Disabil; 2010; 31(6):1561-9. PubMed ID: 20542660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: prevalence and reasons for prescription.
    de Kuijper G; Hoekstra P; Visser F; Scholte FA; Penning C; Evenhuis H
    J Intellect Disabil Res; 2010 Jul; 54(7):659-67. PubMed ID: 20426795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Akathisia in adults with severe and profound intellectual disability: a psychometric study of the MEDS and ARMS.
    Garcia MJ; Matson JL
    J Intellect Dev Disabil; 2008 Jun; 33(2):171-6. PubMed ID: 18569404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dyskinesia Identification System Condensed User Scale (DISCUS): reliability, validity, and a total score cut-off for mentally ill and mentally retarded populations.
    Kalachnik JE; Sprague RL
    J Clin Psychol; 1993 Mar; 49(2):177-89. PubMed ID: 8098048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic dyskinesia examination of profoundly mentally retarded persons: cooperation and assessment.
    Granger DA; Yurkunski JM; Miller NH; Swanson JM; Crinella FC
    Am J Ment Defic; 1987 Sep; 92(2):155-60. PubMed ID: 2893551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychometric properties of the Dyskinesia Identification System: Condensed User Scale (DISCUS).
    Sprague RL; Kalachnik JE; Slaw KM
    Ment Retard; 1989 Jun; 27(3):141-8. PubMed ID: 2739567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychotropic drug use in intellectually disabled group-home residents with behavioural problems.
    Stolker JJ; Koedoot PJ; Heerdink ER; Leufkens HG; Nolen WA
    Pharmacopsychiatry; 2002 Jan; 35(1):19-23. PubMed ID: 11819154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychiatric illness in mental retardation: an update on pharmacotherapy.
    Masi G; Luccherino L
    Panminerva Med; 1997 Dec; 39(4):299-304. PubMed ID: 9478071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of tardive dyskinesia in geropsychiatric outpatients.
    Chacko RC; Root L; Marmion J; Molinari V; Adams GL
    J Clin Psychiatry; 1985 Feb; 46(2):55-7. PubMed ID: 2857168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychotropic medication in adults with mental retardation: prevalence, and prescription practices.
    Holden B; Gitlesen JP
    Res Dev Disabil; 2004; 25(6):509-21. PubMed ID: 15541629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions.
    Dean CE; Kuskowski MA; Caligiuri MP
    J Clin Psychopharmacol; 2006 Dec; 26(6):560-5. PubMed ID: 17110811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Behavior problems in adults with mental retardation. Psychopharmaceuticals are used too often--pedagogical efforts would be better].
    Näslund I
    Lakartidningen; 2007 Apr 4-17; 104(14-15):1132-5. PubMed ID: 17472101
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessment of Drug-Associated Extrapyramidal Symptoms in People With Intellectual Disability: A Comparison of an Informant-Based Scale With Clinical Rating Scales.
    de Kuijper GM; Hoekstra PJ
    J Clin Psychopharmacol; 2016 Oct; 36(5):508-12. PubMed ID: 27529770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of spontaneous dyskinesia in schizophrenia.
    Fenton WS
    J Clin Psychiatry; 2000; 61 Suppl 4():10-4. PubMed ID: 10739325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological management of challenging behavior of individuals with intellectual disability.
    McGillivray JA; McCabe MP
    Res Dev Disabil; 2004; 25(6):523-37. PubMed ID: 15541630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.